Cutaneous Lymphomas

Case 1: Folliculotropic mycosis fungoides with central nervous system involvementCase 2: Erythema gyratum repens-like mycosis fungoides with large cell transformationCase 3: Eczema molluscatum in a patient with erythrodermic mycosis fungoidesCase 4: Parakeratosis variegata-like poikilodermatous CD8+ mycosis fungoidesCase 5: Parakeratosis variegata in a patient with CD8+ mycosis fungoides with post-inflammatory hypopigmentationCase 6: Poikilodermatous mycosis fungoidesCase 7: Tumor mycosis fungoides with xanthomatized atypical lymphocytesCase 8: CD20+ mycosis fungoides partially responsive to rituximabCase 9: Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) in a patient with granulomatous mycosis fungoides and multiple tumorsCase 10. Folliculotropic mycosis fungoides with exuberant neutrophil-rich scale and follicular plugging mimicking hypertrophic actinic keratosisCase 11. Small plaque parapsoriasis-like mycosis fungoidesCase 12. Extragenital lichen sclerosus et atrophicans mimicking hypopigmented mycosis fungoidesCase 13: T-cell-rich angiomatoid polypoid pseudloymphoma (TRAPP) of the skinCase 14. Pustular Sezary syndromeCase 15. De novo expression of CD26 on Sezary cells as an indicator of the disease progression in a patient with Sezary syndromeCase 16. Sezary syndrome presenting with papuloerythroderma of Ofuji and leonine faciesCase 17. Mycosis fungoides-like presentation of primary cutaneous anaplastic large cell lymphomaCase 18. Anaplastic lymphoma kinase-positive primary cutaneous anaplastic large cell lymphomaCase 19. Successful treatment of primary cutaneous anaplastic large cell lymphoma on the penile shaft with brentuximab vedotin and allogenic stem cell transplantCase 20. Lymphomatoid papulosis type D in a child with CD8+ hypopigmented mycosis fungoidesCase 21. Lymphomatoid papulosis and autoimmunityCase 22. Infusion-related CD30-positive lymphomatoid drug eruption secondary to melphalanCase 23. Arthropod reaction with CD30 positive infiltrate and ulceration mimicking CD30 lymphoproliferative disorderCase 24: Extranodal NK/T-cell lymphoma, nasal typeCase 25. EBV-associated extranodal NK/T-cell lymphoma with γ/δ TCR expression presented as aphthous stomatitisCase 26. Extranodal NK/T-cell lymphoma, extra-nasal typeCase 27: Disseminated extranodal NK/T-cell lymphomaCase 28. Primary cutaneous γδ T-cell lymphoma with mycosis fungoides-like plaquesCase 29. Indolent primary cutaneous δ T-cell lymphoma mimicking mycosis fungoidesCase 30. Primary cutaneous γδ T-cell lymphoma with poor response to the therapyCase 31. Primary cutaneous unilateral non-cytotoxic δ T-cell lymphoma slowly progressing into tumorsCase 32. Primary cutaneous γδ T cell lymphoma with panniculitis-like presentationCase 33: Primary cutaneous aggressive epidermotropic CD8-positive T-cell lymphoma with initial protracted courseCase 34. Primary cutaneous aggressive epidermotropic T-cell lymphoma (PC-AETCL) with an aberrant immune phenotypeCase 35. CD8+ T-cell lymphoma with cytotoxic phenotypeCase 36. Primary cutaneous aggressive epidermotropic T-cell lymphoma as a composite lymphoma with B-cell chronic lymphocytic leukemiaCase 37: Primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma with bullous manifestationCase 38. Leukemoid reaction mimicking aggressive epidermotropic CD8+ T-cell lymphomaCase 39. Cutaneous relapse of peripheral T-cell lymphoma, NOS by extensionCase 40. Generalized lymphadenopathy and poikiloderma due to prolonged interferon-β-1
About the Author: Dr. Akilov is an Assistant Professor at the Department of Dermatology and a Director of Cutaneous Lymphoma Program at the University of Pittsburgh. 60% of his time devoted to clinical work when he sees the patient in the outpatient setting as well as a consulting physician for inpatient dermatology cases. Dr. Akilov is a principal investigator on various clinical trials in cutaneous lymphoma. As an independent investigator, Dr. Akilov's research focuses on the pathogenesis of mycosis fungoides and Sézary syndrome, biomarker discovery, and novel therapeutics and is supported by private foundations and pharmaceutical companies. Dr. Akilov is an active national and international teacher giving more than 20 lectures a year. Dr. Akilov serves on the Board of Directors of the United States Cutaneous Lymphoma Consortium. Dr. Akilov authored more than 70 publications in peer-reviewed journals, including around 40 on the subject of cutaneous lymphoma, three book chapters, and more than 200 of conference abstracts and proceedings.